The efficacy of poly-D,L-lactic acid- and hyaluronic acid-coated bone substitutes on implant fixation in sheep

Andreasen, Christina Møller; Snoek Henriksen, Susan; Ding, Ming; Theilgaard, Naseem; Levin Andersen, Thomas; Overgaard, Søren

Published in:
Journal of Orthopaedic Translation

DOI:
10.1016/j.jot.2016.07.002

Publication date:
2017

Document version
Final published version

Document license
CC BY-NC-ND

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
The efficacy of poly-D,L-lactic acid- and hyaluronic acid-coated bone substitutes on implant fixation in sheep

Christina M. Andreasen a,*, Susan S. Henriksen a, Ming Ding a, Naseem Theilgaard b, Thomas L. Andersen c, Søren Overgaard a

a Orthopaedic Research Laboratory, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, J. B. Winsloewsvej 15 Ground floor, DK-5000 Odense C, Denmark
b Danish Technological Institute, Gregersensvej 1, 2630 Taastrup, Denmark
c Department of Clinical Cell Biology (KCB), Vejle Hospital—Lillebaelt Hospital, Institute of Regional Health Research, University of Southern Denmark, Vejle, Kabeltoft 25, DK-7100 Vejle, Denmark

Received 20 May 2016; received in revised form 15 July 2016; accepted 25 July 2016
Available online 25 August 2016

Summary Background/Objective: The present study investigated the efficacy of poly-D,L-lactic acid (PDLLA) and hyaluronic acid (HyA) on implant fixation when coated onto hydroxyapatite/beta-tri-calcium phosphate (HA/bTCP) granules.

Methods: The effect was assessed in a clinically relevant in vivo gap model in sheep. Thus, four titanium implants combined with either allograft (control), pure HA/bTCP, HyA infiltrated HA/bTCP, or PDLLA reinforced HA/bTCP granules were bilaterally inserted into the trabecular bone of the distal femurs in eight sheep. The insertion created a 2-mm peri-implant gap. After 12 weeks, histomorphometry and push-out test was used for quantification of newly formed bone in the gap, bone-implant contact, and implant fixation.

Results: The histomorphometric analysis revealed the presence of newly formed bone in all groups, though substitute groups showed fragments of nonabsorbed substitute material. A significant larger bone volume was found in the allograft group versus the HA/bTCP-PDLLA group (Zone 1), and in Zone 2 a statistically significantly larger bone volume was found in the allograft compared with the HA/bTCP group. The mechanical properties and the bone-implant contact revealed no statistically significant differences between the groups.

Conclusion: This study demonstrates that HA/bTCP granules coated with PDLLA and HyA have similar bone ingrowth and implant fixation as those with allograft, and with mechanical properties resembling those of allograft in advance, they may be considered as alternative substitute materials for bone formation in sheep.

* Corresponding author. Orthopaedic Research Laboratory, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, J. B. Winsloewsvej 15 Ground floor, DK-5000 Odense C, Denmark.
E-mail address: cmandreasen@health.sdu.dk (C.M. Andreasen).

http://dx.doi.org/10.1016/j.jot.2016.07.002
2214-031X/© 2016 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The number of total joint replacement surgeries is increasing each year due to an expanding elderly population. Additionally, a rise in the number of failure rate revision surgeries has been explored, mainly explained by an impaired bone formation around the implants [1]. Damaged bone is often replaced by metal implants, providing the strength and stiffness required for most load-bearing bone sites [2,3]. However, insertion of implants often also demands supplement of either donor bone or bone substitutes to secure a proper implant fixation [3,4].

To improve the efficacy and functionality of implants, lots of effort has been put into the development of new bone substitutes used in combination with those metal alloys. An optimal bone substitute has a high biocompatibility, promotes early bone formation at the bone-implant interface, and retains a suitable strength required at the particular skeletal site [5,6]. All these factors are essential for long-term implant survival, being of both social and economic importance.

Bioceramics, such as beta-tricalcium phosphate (βTCP) and hydroxyapatite (HA), are known to be very compatible with the human body environment inducing a biological response similar to bone [7,8]. Due to their osteoconductive properties, βTCP and HA are often combined, although their mechanical properties are not entirely comparable to that of bone [3,4]. Research has shown that the mechanical performance of HA/βTCP-ceramics can be enhanced by reinforcement with polymers, e.g., poly-ε-lactic acid (PDLLA), poly-glycolic acid, or poly-hydroxy butyrate [3,9].

PDLLA, a long-chained polymer degraded into lactic acid by the tricarboxylic acid cycle, is ideal due to its biocompatibility, strength, and high solubility [9,10]. Recent investigation has shown that the addition of 10–15% PDLLA to HA/βTCP scaffolds significantly increases their strength [11,12]. Additionally, in vivo studies have revealed that HA substitutes combined with PDLLA induce bone formation around titanium implants [12–14]. Another polymer with favourable bone-stimulating properties is hyaluronic acid (HyA). HyA is a polysaccharide and an important component of the extracellular matrix exhibiting several beneficial chemical properties, i.e., therapeutic agent in arthritis therapy and anti-inflammatory agent in animal models [15]. Further, it promotes osteoblast differentiation, thereby stimulating bone formation, as shown in rat calvarial-derived cell cultures [16] and rat cortical bone [17].

Although the infiltration of HA/βTCP scaffolds with HyA seems not to improve the mechanical properties [11], HyA shows good osteoconductive properties, therefore still considered a resilient composite material. Consequently, it is interesting to evaluate whether HA/βTCP-PDLLA and HA/βTCP-HyA could positively affect the fixation of titanium implants in a clinically relevant large animal model.

The aim of the present study was to investigate the efficacy of HA/βTCP granules reinforced with PDLLA or infiltrated with HyA on the fixation of titanium implants bilaterally inserted into a gap model in sheep. We hypothesized that HA/βTCP substitutes added PDLLA and HyA were able to conduct formation of bone at the bone-implant interphase promoting an appropriate mechanical fixation.

Materials and methods

Eight female sheep of the Merino/Gotland wool mixed breed were used. Their mean age was 4 years (range, 3–5 years) while their mean body weight was 78.0 ± 7.4 kg. The sheep were housed in outdoor paddocks and were fed hay and compound feed throughout the experiment. The animals were housed indoors at the central animal facility 1 week prior to surgery and 2–3 days postoperation. All institutional and national guidelines for the care and use of laboratory animals were followed, and the Danish Animal Experiments Inspectorate approved the study (number: 2011/561-1959).

Study design

In this study, 32 cylindrical plasma-sprayed titanium alloys (90% titanium, 6% aluminium, 4% vanadium; Biomet, Warsaw, IN, USA; Figure 1A) were bilaterally implanted into a gap model, as previously described [18,19]. The implants were inserted extra-articularly into trabecular bone of the medial and lateral distal femoral condyles, clearly separated to avoid any potential interference between the implanted substitute materials. The implants were 10 mm high and had a column diameter of 6 mm. The footplate and top washer were 10 mm in diameter, giving a circumferential gap of 2 mm and a volume of 0.5 mL (Figure 1B).

The gaps were subsequently filled with one of the four materials: allograft (control), pure HA/βTCP, HA/βTCP-HyA, or HA/βTCP-PDLLA granules. Thus, four different graft materials were implanted in each sheep, serving as their own control. To avoid any site-specific differences, implant materials were alternated between the gaps. Allograft is considered the gold standard in many orthopaedic procedures, thus reflecting a relevant control group in this study [20].

Graft materials

Allograft

The allograft was prepared from the distal femurs and proximal tibiae of a healthy donor sheep of the same age. After removal of cartilage and soft tissue, the bone was milled in a bone mill (Ossano Scandinavia ApS, Stockholm, Sweden) resulting in 0.5–1.5-mm bone graft particles. The bone graft was packed in sterile 1.5-mL vials and preserved at −80 °C until surgery.
Scaffold granules

Porous HA/βTCP granules, consisting of 70% HA and 30% βTCP, were fabricated by the Danish Technological Institute (Taastrup, Denmark). The granules had a particle size of 500–1400 μm and a porosity of approximately 80%. The pore size of the composite graft material was 300–700 μm with an interconnecting pore size of 100–200 μm. HA/βTCP granules infiltrated with the biopolymer HyA [molecular weight (MW) = 650 kDa] provided by Novozymes (Bagsvaerd, Denmark) represented the second group of graft materials. The HyA was coated onto the porous HA/βTCP granules by sterile solvent infiltration based on demineralized water [11]. Briefly, a solution of 3 mL sterile HyA (0.15% w/w) was mixed with 1.5 mL pure HA/βTCP granules and dried under vacuum (room temperature) for 12 hours. The process was repeated until the final concentration of HyA reached 0.15%. The final porosity was approximately 80% [11]. HA/βTCP granules reinforced with an ultrathin layer of 10% PDLLA (50% D-PLA, 50% L-PLA, molecular weight = 308 kDa) to enhance their mechanical strength were provided by PHUSIS (Saint Ismier, France). As previously shown in our lab, they have a porosity of approximately 70% [11,12].

Surgical procedure

As premedication, the animals received 0.2 mg/kg of Rompun (xylancin hydrochloride, 20 mg/mL; Bayer Animal Health GmbH, Leverkusen, Germany). Anaesthesia was induced with 3 mg/kg of Rapinovent (propofol 10 mg/mL; Schering-Plough, Ballerup, Denmark), while the surgical procedures were performed under general anaesthesia (2.0 % isoflurane). Under aseptic conditions, and after iodine disinfection of the lateral femur, the periosteal surface was exposed by an incision through the skin. To prevent any thermal damage of the bone and surrounding tissue, a low-speed drill created a 12-mm deep cylindrical hole with a circumference of 10 mm. To remove residual bone particles, the gap was rinsed with saline before insertion of the implants forming a gap of 2 mm. Subsequently, the concentric gap was randomly filled with one of the four graft materials before the top-washer was tightly placed on the implant. Finally, the wound was sutured in three layers. The procedure was repeated for the medial side as well as the opposite femur. Postoperative analgesia (0.03 mL/mg buprenorphine, Temgesic; Schering-Plough, Ballerup, Denmark) and ampicillin (250 mg/mL ampicillin; Ampivet Vet, Boehringer Ingelheim, Copenhagen, Denmark) was administered daily for 3–4 days [12]. After 12 weeks of observation the sheep were euthanized with an overdose of pentobarbital and both distal femurs were harvested and divided prior to further processing.

Preparation of specimens

The bone implant specimens were cut orthogonally into two parts with an Exakt diamond band saw (Exakt Apparatebau, Norderstedt, Germany). After removal of the top washer, a bone-implant sample of 3.5 mm was prepared and stored at −20°C until assessment of bone-implant fixation by mechanical push-out test. The remaining part of the implant specimen, 5.5 mm, was prepared for histological and histomorphometrical investigations. Briefly, the specimens were dehydrated in graded ethanol series (70–99%) at room temperature, containing 0.4% basic fuchsine, and subsequently embedded in methyl methacrylate (Technovit 9100 NEW; Heraeus Kizier GmbH, Wehrheim, Germany). Using the vertical sectioning method, four sections (approximately 30 μm thick) from each bone specimen (thus 16 sections per sheep) were cut using a microtome (Medeja, Leiden, The Netherlands) and counterstained with 2% light green to visualize mineralized bone [21].

Mechanical testing

Before assessment of the implant failure by a push-out test performed on an 858 Bionix Material Testing System (hydraulic material testing system; MTS Systems Co., Minneapolis, MN, USA), the bone implant specimens were thawed at room temperature for 2 hours (Figure 2B). The diameter of the gap was 10 mm and the diameter of the test-plate hole under the specimen was 10 mm, while the piston pushing out the implant had a diameter of 6 mm (Figure 2A) [12]. The displacement rate was 5 mm/min. Load versus displacement data were recorded and used for calculation of the mechanical parameters—ultimate shear stiffness (MPa), ultimate shear strength (MPa), and failure energy (kJ/cm²) (Figure 2C).
Histology and histomorphometry

We distinguished bone by green/blue surface staining and the presence of osteocytes. Using polarized light, we were able to differentiate between mature lamellar bone with regular parallel alignment of lamellae and immature woven bone, characterized by their randomly oriented collagen fibres and round cell lacunae. Fibrous tissue was stained red and identified by their visible fibril fibres and low cell density, while remnants of substitutes were detected as small grey islets easily identified from the other tissues.

To get unbiased estimates of the anisotropic concentric gaps, four sections from each implant were analysed by point counting (newCAST; Visiopharm, Hørsholm, Denmark) based on the vertical sectioning design [22,23] to quantify the volume of selected tissues: newly formed bone (BV/TV), bone marrow, fibrous tissue, and remnants of unre sorbed HA/TCP granules according to the American Society for Bone and Mineral Research standards [24]. Tissue volumes were quantified in two predefined zones adjacent to the titanium implant: Zone 1, situated close to the implant surface; and Zone 2, next to host bone. Both zones had a width of approximately 500 μm (Figure 3). Subsequently, by linear interception technique, the bone–implant contact (BIC) was estimated for all groups. Generally, each section was analysed blinded in a random order. However, a complete blinding of the sections was not possible due to easy identification of implant materials, although we were not able to distinguish from the different types of substitute material.

Statistical analysis

The statistical significance of the differences between the control and the substitute groups was analysed using repeated measurements one-way analysis of variance or a Friedman’s test. Post hoc multiple comparison analysis was done either by Bonferroni or Dunn’s test. D’Agostino and Pearson omnibus normality test was used to assess the normality of the difference between groups. All graphs and statistical analysis were prepared in GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA, USA). Values of \( p < 0.05 \) were considered statistically significant.

Results

Observations on animals

All eight sheep were able to walk 3 days after surgery and completed the observation period of 12 weeks without any signs of infection or significant weight change.

Mechanical properties

A destructive push-out test assessing the strength of the bone-implant interface revealed no statistically significant difference in the shear stiffness, shear strength, or failure energy between groups (Table 1).

Figure 2  (A) The bone implant interface was investigated by push-out test on a 858 Bionix Material Testing System hydraulic; (B) assessing the implant failure of bone specimens; (C) generation of load-displacement curves.

Figure 3  Schematic view of a titanium implant showing the regions of interest, approximately 500 μm each. Zone 1 is close to the implant and Zone 2 close to host bone (H). N represents the newly formed woven bone.
Histological observations

Existence of newly formed bone in the concentric gaps was found in all groups, with remnants of substitute material in the three substitute groups. The remnants were identified as small grey islets surrounded by new bone, fibrous tissue, or bone marrow (Figure 4). The identified bone consisted only of nonlamellar woven bone, and remnants of allograft were not detected. Further, no signs of infection or fibrocartilage were present in any of the groups.

In four bone specimens, represented by two specimens from the HA/βTCP group, one from the HA/βTCP-PDLLA group, and one from the HA/βTCP-HyA group, the BIC could not be evaluated as no tissues were in direct contact with the implant surface. This could be explained by encapsulation of the implant by fibrous tissue, which may cause a shrinking during preparation of the sections. Consequently, the four specimens were excluded from the BIC analysis.

Histomorphometry

Comparison of the BIC between the groups showed no statistically significant difference (Table 2), while the bone marrow volume was statistically significant, greater in the allograft group (22.1 ± 9.6%) compared with all substitute groups (HA/βTCP: 5.8 ± 8.1%, HA/βTCP-PDLLA: 5.1 ± 4.3%, HA/βTCP-HyA: 5.0 ± 6.4%).

The allograft group showed a statistically significantly larger BV/TV in Zone 1 (31.6 ± 13.0%) compared with the HA/βTCP-PDLLA group (18.5 ± 10.6%), whereas in Zone 2 the BV/TV was significantly larger for allograft (37.7 ± 16.0%) in comparison to the HA/βTCP group (22.2 ± 7.4%; Table 3).

The volume of fibrous tissue was statistically significantly larger in both zones comparing allograft (Zone 1: 36.9 ± 19.0%, Zone 2: 29.0 ± 19.7%) and the HA/βTCP group (Zone 1: 21.5 ± 8.5%, Zone 2: 12.7 ± 4.2%). However, the bone marrow volume revealed no statistically significant difference between the groups, and neither there was any significant difference in the amount of residual substitutes between the substitute groups (Table 3).

Discussion

The purpose of this study was to investigate whether HA/βTCP-HyA or HA/βTCP-PDLLA granules could conduct bone formation for proper implant fixation in a gap model in sheep. According to the histomorphometric evaluation, the allograft group showed a larger BV/TV when compared with the HA/βTCP-PDLLA group (Zone 1). Despite the lowered bone formation in the HA/βTCP-PDLLA group, no statistically significant differences in the mechanical properties as well as the BIC were detected, comparing both HA/βTCP-PDLLA and HA/βTCP-HyA to the allograft. Consequently, the data support our hypothesis that HA/βTCP-PDLLA and HA/βTCP-HyA can conduct an efficient formation of bone and subsequent implant fixation in sheep, demonstrating their continued relevance as synthetic bone substitutes.

The histological investigation revealed the formation of new bone in the gap of all groups. The significantly lower BV/TV in Zone 1 of the HA/βTCP-PDLLA group compared with the allograft group could indicate reduced osteoconductive properties of PDLLA. This is consistent with another study conducted in sheep, showing a delayed formation of bone in gaps filled with PDLLA-coated HA/βTCP substitutes compared with pure substitutes [25]. A lowered porosity of substitute material due to PDLLA coating could explain the reduced bone formation, though the porosity is considered within the limit ensuring optimal bone ingrowth.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Mechanical shear properties assessed by push-out test.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Shear stiffness (MPa)</td>
</tr>
<tr>
<td>G1: Allograft</td>
<td>4.8 ± 4.1</td>
</tr>
<tr>
<td>G2: HA/βTCP</td>
<td>8.2 ± 9.5</td>
</tr>
<tr>
<td>G3: HA/βTCP-HyA</td>
<td>6.6 ± 7.3</td>
</tr>
<tr>
<td>G4: HA/βTCP-PDLLA</td>
<td>6.2 ± 6.0</td>
</tr>
<tr>
<td>RM one-way ANOVA (p)</td>
<td>p = 0.86</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation. n = 8 for all groups.

ANOVA = analysis of variance; HA/βTCP = hydroxyapatite/beta-tri-calcium phosphate; HyA = hyaluronic acid; PDLLA = poly-D,L-lactic acid; RM = repeated measures.

Figure 4  (A) Histological section representing the allograft group; (B) histological section representing the hydroxyapatite/beta-tri-calcium phosphate group. The presence of newly formed bone (B), fibrous tissue (F), bone marrow (M), and nonabsorbed substitutes (S) are marked on the pictures (magnification ×10).
Efficacy of coated bone substitutes

Regarding the BIC, numerically higher values were TCP group compared with the others, although not statistically significant differences in the mechanical properties between the groups were observed. This indicates that HA/βTCP-HyA and HA/βTCP-PDLLA offer similar shear strength, modulus, and failure energy on implant fixation to those of allograft. With mechanical properties and a BIC similar to allograft, PDLLA reinforced HA/βTCP showed promising results as an alternative bone substitute consistent with recent studies, where PDLLA coated HA improved the implant performance in sheep [12,14,19] and rabbit [13]. Moreover, HA/βTCP

Table 2: Histomorphometric data of the bone-implant contact in percentage of the total implant surface.

<table>
<thead>
<tr>
<th>Group</th>
<th>BV/TV (%)</th>
<th>Fb.V/TV (%)</th>
<th>Ma.V/TV (%)</th>
<th>Remnant substitute (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1: Allograft</td>
<td>13.0 ± 10.7</td>
<td>61.2 ± 17.0</td>
<td>22.1 ± 9.6</td>
<td>—</td>
</tr>
<tr>
<td>G2: HA/βTCP</td>
<td>22.0 ± 12.0</td>
<td>69.5 ± 17.4</td>
<td>5.8 ± 8.1</td>
<td>4.1 ± 6.4</td>
</tr>
<tr>
<td>G3: HA/βTCP-HyA</td>
<td>10.8 ± 9.3</td>
<td>77.3 ± 8.1</td>
<td>5.1 ± 4.3</td>
<td>2.9 ± 3.1</td>
</tr>
<tr>
<td>G4: HA/βTCP-PDLLA</td>
<td>12.6 ± 7.2</td>
<td>73.2 ± 15.9</td>
<td>5.0 ± 6.4</td>
<td>3.6 ± 1.8</td>
</tr>
<tr>
<td>RM one-way ANOVA (p)</td>
<td>p = 0.93</td>
<td>p = 0.73</td>
<td>p &lt; 0.001</td>
<td>p = 0.93</td>
</tr>
<tr>
<td>Diff. between groups</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation.
ANOVA = analysis of variance; BV/TV = bone volume; Diff. = difference; Fb.V/TV = fibrous tissue volume; HA/βTCP = hydroxyapatite/beta-tri-calcium phosphate; HyA = hyaluronic acid; Ma.V/TV = bone marrow volume; PDLLA = poly-D,L-lactic acid; RM = repeated measures.

Table 3: Histomorphometric data showing the percentage of bone volume per tissue volume in Zone 1 and Zone 2.

<table>
<thead>
<tr>
<th>Zone 1</th>
<th>BV/TV (%)</th>
<th>Fb.V/TV (%)</th>
<th>Ma.V/TV (%)</th>
<th>Remnant substitute (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1: Allograft</td>
<td>31.6 ± 13.0</td>
<td>36.9 ± 19.0</td>
<td>22.5 ± 16.9</td>
<td>—</td>
</tr>
<tr>
<td>G2: HA/βTCP</td>
<td>22.3 ± 6.7</td>
<td>21.5 ± 8.5</td>
<td>16.2 ± 10.7</td>
<td>35.6 ± 13.7</td>
</tr>
<tr>
<td>G3: HA/βTCP-HyA</td>
<td>24.5 ± 12.8</td>
<td>25.6 ± 17.5</td>
<td>15.7 ± 17.5</td>
<td>30.8 ± 8.6</td>
</tr>
<tr>
<td>G4: HA/βTCP-PDLLA</td>
<td>18.5 ± 10.6</td>
<td>24.3 ± 13.2</td>
<td>15.1 ± 7.4</td>
<td>35.1 ± 13.1</td>
</tr>
<tr>
<td>RM one-way ANOVA (p)</td>
<td>p &lt; 0.05</td>
<td>p &lt; 0.05</td>
<td>p = 0.67</td>
<td>p = 0.67</td>
</tr>
<tr>
<td>Diff. between groups</td>
<td>G1 &gt; G4</td>
<td>G1 &gt; G2</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zone 2</th>
<th>BV/TV (%)</th>
<th>Fb.V/TV (%)</th>
<th>Ma.V/TV (%)</th>
<th>Remnant substitute (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1: Allograft</td>
<td>37.7 ± 16.0</td>
<td>29.0 ± 19.7</td>
<td>27.0 ± 12.8</td>
<td>—</td>
</tr>
<tr>
<td>G2: HA/βTCP</td>
<td>22.2 ± 7.4</td>
<td>12.7 ± 4.2</td>
<td>24.9 ± 9.5</td>
<td>35.1 ± 12.8</td>
</tr>
<tr>
<td>G3: HA/βTCP-HyA</td>
<td>33.0 ± 12.8</td>
<td>14.0 ± 9.5</td>
<td>18.6 ± 15.0</td>
<td>31.4 ± 15.0</td>
</tr>
<tr>
<td>G4: HA/βTCP-PDLLA</td>
<td>24.6 ± 11.8</td>
<td>21.0 ± 12.2</td>
<td>18.2 ± 9.9</td>
<td>30.5 ± 10.9</td>
</tr>
<tr>
<td>RM one-way ANOVA (p)</td>
<td>p &lt; 0.05</td>
<td>p &lt; 0.05</td>
<td>p = 0.29</td>
<td>p = 0.46</td>
</tr>
<tr>
<td>Diff. between groups</td>
<td>G1 &gt; G2</td>
<td>G1 &gt; G2</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation.
n = 8 for all groups.
ANOVA = analysis of variance; BV/TV = bone volume; Diff. = difference; Fb.V/TV = fibrous tissue volume; HA/βTCP = hydroxyapatite/beta-tri-calcium phosphate; HyA = hyaluronic acid; Ma.V/TV = bone marrow volume; PDLLA = poly-D,L-lactic acid; RM = repeated measures.
scaffolds reinforced with 10% PDLLA has been shown to attain mechanical properties similar to that of human cancellous bone [11,13]. We decided to investigate the effect of high molecular weight (MW) HyA, because this form of HyA is reported to stimulate the formation of bone as well as supporting an osteogenic differentiation of bone marrow stem cells [16,31]. Its presence in callus during fracture healing in rabbits further supports its potential as a bone ingrowth stimulator [32]. Our results showed that HyA infiltrated HA/βTCP granules could conduct a bone formation and implant fixation comparable to that of allograft. This is in consistence with previous studies showing bone ingrowth around HyA-coated titanium implants in rabbit femurs [33,34]. Other studies have reported increased osteoblastic activity [16] and more bone formation in rats when applied to bone wounds [17]. Borsari and coworkers [35] were, nevertheless, not able to detect any significant differences in bone ingrowth between HyA-coated or uncoated titanium implants inserted in young, aged, and ovariectomized sheep, respectively.

An apparent limitation of the present study is the small number of animals included, reducing the power of the study. However, the gaps were systematically filled with allograft or substitute, and each animal served as their own control reducing the biological variation among the individuals. Insertion of the implants into a nonweight-bearing position and the fact that the load on the skeletal sites in sheep is different from humans points out another weakness of the study prohibiting a direct extrapolation to patients. However, the design enables an investigation of the selected bone substitutes in a more controlled milieu avoiding the influence of, for example, synovial fluids. Overall, HA/βTCP-PDLLA and HA/βTCP-HyA exhibited an osteoconductive potential correspondent to allograft, signifying their promising properties as bone graft substitutes in a large animal model.

Conclusion

This study has demonstrated that HA/βTCP granules reinforced with PDLLA or infiltrated with HyA had similar bone ingrowth and implant fixation as those with allograft.

In perspective, mechanical properties resembling those of allograft in advance, the bone substitutes may be considered as alternatives to allograft for bone healing in this sheep model.

Conflicts of interest

The authors have no conflicts of interest relevant to this article.

Funding/support

Odense University Hospital Free Research Fund (numbers: 700-701-003-316, 1021-1912), and University of Southern Denmark (number: 2010-11202; 1-year PhD fellowship for CMA) supported the study.

Acknowledgments

We are thankful to Gitte Højlund Reinberg for her excellent technical assistance, Maria Vinther Juhl (Danish Technological Institute) for assisting with the HyA-coating procedure, Birgitte Mølholm Malle (Novozymes A/S) for kindly donating the HyA solution, and the staff of the Biomedical Laboratory for taking good care of the animals.

References

[18] Babiker H, Ding M, Sandri M, Tampieri A, Overgaard S. The effects of bone marrow aspirate, bone graft, and collagen


